Energy & Environmental Law Adviser
Product Liability & Mass Torts Blog
Employment Law Landscape
Paragraph IV Disputes Master Symposium – ACI’s Hatch-Waxman Series
4th Annual IP Strategy Summit: Chicago
Women in Bio Chicago Chapter
7th Annual Pharma IPR Conference 2018
Chicago Women in IP
Intellectual Property Owners Association
Managing Intellectual Property Innovation and Litigation Summit 2019
Law360, The Wall Street Journal, Thomson Reuters, Bloomberg Business, AmLaw Daily, Deal Pipeline, LSIPR, IP Pro Life Sciences
The Cybersecurity Law Report
Schiff Hardin is pleased to have been counsel to E&M Ice Cream in a transaction that was recently awarded the “U.S.A. ESOP Deal of the Year” at the 2016 Americas M&A Atlas Awards by Global M&A Network.
BTI’s Power Ranking 2016 recognized Schiff Hardin in its top category—Clientopia®—for the firm’s work on behalf of the pharmaceutical industry.
Schiff Hardin LLP is pleased to announce that three practice groups and eight attorneys have been recognized in the 2016 edition of the Legal 500.
World Intellectual Property Review
For the second consecutive year, Schiff Hardin has been recognized as a top “Clientopia” law firm in the BTI Industry Power Rankings 2017.
Schiff Hardin LLP is pleased to announce that Imron Aly, partner and Intellectual Property Group co-leader, has been recognized as a Most Influential Minority Lawyer in Chicago by Crain’s Chicago Business.
Schiff Hardin Intellectual Property Practice Group Co-Leader Imron Aly has been recognized as a leading patent litigator in Illinois in the 2017 IAM Patent 1000 guide, based on outstanding feedback from peers and clients.
Schiff Hardin has been ranked “Highly Recommended” by Managing Intellectual Property magazine in the 2017 Illinois Patent Contentious category.
Today Muhammad Ali Enterprises filed a complaint in the United States District Court for the Northern District of Illinois against Fox Broadcasting Company seeking in excess of $30 million in damages for Fox’s unauthorized use of Muhammad Ali’s identity in a promotional video that Fox broadcast immediately before the start of Fox’s broadcast of the 2017 Super Bowl.
Center for Biosimilars
The National Law Journal
Schiff Hardin LLP today announced the addition of Kevin M. Nelson as a partner in its rapidly growing Intellectual Property Group.
Schiff Hardin LLP has been ranked as a “Recommended Firm” in Illinois in the 2018 edition of Benchmark Litigation, an annual guide to the leading litigation firms and attorneys in the United States.
Schiff Hardin LLP has been recognized as one of the top law firms defending Abbreviated New Drug Application (ANDA) litigation in the 2017 Hatch-Waxman/ANDA Litigation Report compiled by legal data analytics firm Lex Machina.
Imron Aly and Sailesh Patel have been named Life Sciences Stars in the Hatch-Waxman Patent Litigation Practice Area by LMG Life Sciences in its 2018 guide.
The Center for Biosimilars
Schiff Hardin is pleased to announce that four practice areas and 22 attorneys have been recognized in the 2018 edition of Chambers USA, a leading legal industry ranking.
Leading Lawyers Magazine – 2018 Business Edition
Schiff Hardin is proud to announce that Intellectual Property Practice Group Co-Leader Imron Aly has been recognized in the seventh edition of IAM Patent 1000.
Schiff Hardin LLP has been singled out by corporate counsel as one of only 28 percent of law firms clients view as a BTI “Innovation Builder,” which recognizes firms that bring change to the legal market through new technology, services, strategies, or structures.
Schiff Hardin has been ranked as ‘Recommended’ by Managing Intellectual Property magazine in the Illinois IP Stars Patent Contentious category.
Schiff Hardin successfully secured a favorable outcome for our client, Fresenius Kabi USA LLC, in a patent-infringement suit filed by Hospira Inc., which paves the way for Fresenius to market a new generic drug.
Schiff Hardin LLP is pleased to announce that three of its practice groups have been recognized for the third consecutive year by The Legal 500 United States 2018 guide, a nationwide analysis of law firms with input from more than 300,000 corporate counsel on which firms provide the most cutting-edge and innovative advice.
Intellectual Property Practice Group Co-Leader Imron Aly has joined the advisory board for the Center for Biosimilars, an online resource for emerging pharmaceutical biotechnology that discusses the current landscape for advanced health care management with top industry thought leaders.
Schiff Hardin is pleased to announce that four practice areas and 23 attorneys have been recognized in the 2019 edition of Chambers USA, a leading legal industry ranking.
Partner George Yu has been selected for the Law360 2019 Life Sciences Editorial Advisory Board. According to Law360, the purpose of the nine-lawyer board is to gain insight from experts in the field on how best to shape future coverage.
Schiff Hardin LLP is proud to announce that the firm and three of its attorneys have been ranked in the eighth edition of IAM Patent 1000: The World’s Leading Patent Professionals.
Schiff Hardin is pleased to announce that the firm has been ranked as ‘Recommended’ by Managing Intellectual Property magazine in the Illinois IP Stars Patent Contentious category, which includes dispute resolution work, litigation and enforcement, as well as Hatch-Waxman, International Trade Commission, and multinational litigation work.
Biosimilars Review & Report
Schiff Hardin LLP is pleased to announce that three of the firm’s practice groups have been recognized for the fourth year in a row in The Legal 500 United States 2019 guide, which provides a nationwide analysis of law firms that provide cutting-edge and innovative advice.
Three Schiff Hardin attorneys were also recognized in New York Women’s Edition—Rising Stars.
Mark September 26, 2016, on your calendar as the deadline to tell the DOJ and FTC what should be changed, or not, in the Antitrust Guidelines for the Licensing of Intellectual Property.
The Court of Appeals for the Federal Circuit reversed over 30 years of precedent as it held unconstitutional the Section 2(a) disparagement bar of the Lanham Act on December 22, 2015.
Chapter 16 in Intellectual Property Law, IICLE (2017)
Recently enacted federal civil trade secret legislation immediately impacts the way non-disclosure agreements should be drafted.
Supreme Court Holds that Decision to Institute IPR is Non-appealable and PTAB’s “Broadest Reasonable Construction” Standard for Claim Construction is Lawful
Schiff Hardin’s pharma and life sciences patent litigation team, lead by partner Imron T. Aly, recently secured a preliminary injunction in federal court.
The Eighth Circuit affirmed a $2.57 million damages award and permanent injunction in favor of Warner Bros., protecting its copyrights and trademarks in The Wizard of Oz, Gone With the Wind, and Tom & Jerry cartoons.
Trade secrets now enjoy the same type of federal protection afforded other forms of intellectual property, like trademarks, copyrights and patents.
IPRs have become a common, attractive tool for patent challengers because of their more favorable standard of review and one-year deadline to final written decision.
Pfizer sued Johnson & Johnson (J&J) in federal court in Pennsylvania last week, alleging anticompetitive discounts and other actions to prevent competition with J&J’s biologic Remicade.
The U.S. Supreme Court’s Lee v. Tam decision struck down a provision of the federal trademark law.
Earlier this week, the U.S. Supreme Court unanimously held, in its first case interpreting the Biologics Price Competition and Innovation Act of 2009, Sandoz Inc. v. Amgen Inc.
Decades ago, antitrust enforcement officials developed the “9 No-No’s” regarding patents and licenses. The days of antitrust hostility toward intellectual property are behind us, but renewed tension between antitrust and intellectual property policy seems to be growing.
The Supreme Court recently agreed to hear a challenge to the current interpretation of the venue statute in patent infringement cases.
Like generic drugs in the 1980s, biosimilars today face a number of regulatory, legal, scientific, and public perception obstacles to continued growth.
Schiff Hardin Product Liability & Mass Torts Blog
Today’s oral arguments in Supreme Court case Helsinn Healthcare v. Teva illustrate the power that a successful appeal could have to change a longstanding doctrine and significantly impact how businesses handle intellectual property transactions.
The Pharma Letter
In the quick pound of a gavel, the entire U.S. pharmaceutical and biologics industries were thrown into doubt after Judge Reed O’Connor of the United States District Court for the Northern District of Texas found the individual mandate of the Affordable Care Act (ACA) – and therefore the entire act – unconstitutional.
As the government shutdown stretches on, pharmaceutical companies must manage the partial shutdown of the U.S. Food and Drug Administration (FDA).
Pfizer’s recent decision not to disclose data about Enbrel’s potential to treat Alzheimer’s disease has caused much debate about drugmakers’ obligations to the public.